Use of botulinum toxin type a in temporomandibular disorder

ABSTRACT Temporomandibular disorder (TMD) may be defined as a set of clinical scenarios involving the masticatory muscles, the temporomandibular joint (TMJ) and associated structures. Currently, 40 to 75% of the population has some sign of temporomandibular disorder, mainly pain located in the muscles of mastication in the pre-auricular region. The present clinical case was diagnosed as muscle temporomandibular disorder secondary to parafunction, as well as muscle hyperactivity due to surgical displacement of the left temporal muscle on two occasions, one for placement of aneurysm clips and the other for tumor excision from the supraorbital region on the left side. The patient sought medical and dental attention for 10 years due to constant headaches, tiredness and pain in the cheeks. The patient tried numerous bite-guards and pharmacological therapies to no avail. The American Academy of Orofacial Pain Questionnaire was applied combined with the Criteria for Research and Diagnostics (DRC) and a decision was made to use botulinum toxin type A in the masseter and temporalis muscles. An analog pain scale was applied over 90 days. Three days following the application of botulinum toxin type A, the patient reported a significant improvement with complete resolution of pain (level 0) after 90 days. At 12 weeks from starting treatment, facial muscle physiotherapy was introduced to strengthen the muscles of mastication and the patient remained pain-free, which allowed the preparation and adaptation of a snap-on prosthetic appliance. In conclusion, the use of botulinum toxin in patients with temporomandibular disorder should be considered as a viable therapeutic option.

Saved in:
Bibliographic Details
Main Authors: HUAMANI,Mary Akemy Uehara, MOREIRA,Luciano Artioli, ARAÚJO,Ney Soares de, NAPIMOGA,Marcelo Henrique, JUNQUEIRA,José Luiz Cintra, MIRANDA,Milton Edson
Format: Digital revista
Language:English
Published: Faculdade São Leopoldo Mandic 2017
Online Access:http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1981-86372017000200151
Tags: Add Tag
No Tags, Be the first to tag this record!
id oai:scielo:S1981-86372017000200151
record_format ojs
spelling oai:scielo:S1981-863720170002001512019-08-07Use of botulinum toxin type a in temporomandibular disorderHUAMANI,Mary Akemy UeharaMOREIRA,Luciano ArtioliARAÚJO,Ney Soares deNAPIMOGA,Marcelo HenriqueJUNQUEIRA,José Luiz CintraMIRANDA,Milton Edson Botulinum toxins type A. Dentistry. Temporomandibular joint disorders. ABSTRACT Temporomandibular disorder (TMD) may be defined as a set of clinical scenarios involving the masticatory muscles, the temporomandibular joint (TMJ) and associated structures. Currently, 40 to 75% of the population has some sign of temporomandibular disorder, mainly pain located in the muscles of mastication in the pre-auricular region. The present clinical case was diagnosed as muscle temporomandibular disorder secondary to parafunction, as well as muscle hyperactivity due to surgical displacement of the left temporal muscle on two occasions, one for placement of aneurysm clips and the other for tumor excision from the supraorbital region on the left side. The patient sought medical and dental attention for 10 years due to constant headaches, tiredness and pain in the cheeks. The patient tried numerous bite-guards and pharmacological therapies to no avail. The American Academy of Orofacial Pain Questionnaire was applied combined with the Criteria for Research and Diagnostics (DRC) and a decision was made to use botulinum toxin type A in the masseter and temporalis muscles. An analog pain scale was applied over 90 days. Three days following the application of botulinum toxin type A, the patient reported a significant improvement with complete resolution of pain (level 0) after 90 days. At 12 weeks from starting treatment, facial muscle physiotherapy was introduced to strengthen the muscles of mastication and the patient remained pain-free, which allowed the preparation and adaptation of a snap-on prosthetic appliance. In conclusion, the use of botulinum toxin in patients with temporomandibular disorder should be considered as a viable therapeutic option.info:eu-repo/semantics/openAccessFaculdade São Leopoldo MandicRGO - Revista Gaúcha de Odontologia v.65 n.2 20172017-06-01info:eu-repo/semantics/articletext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S1981-86372017000200151en10.1590/1981-863720170002000093144
institution SCIELO
collection OJS
country Brasil
countrycode BR
component Revista
access En linea
databasecode rev-scielo-br
tag revista
region America del Sur
libraryname SciELO
language English
format Digital
author HUAMANI,Mary Akemy Uehara
MOREIRA,Luciano Artioli
ARAÚJO,Ney Soares de
NAPIMOGA,Marcelo Henrique
JUNQUEIRA,José Luiz Cintra
MIRANDA,Milton Edson
spellingShingle HUAMANI,Mary Akemy Uehara
MOREIRA,Luciano Artioli
ARAÚJO,Ney Soares de
NAPIMOGA,Marcelo Henrique
JUNQUEIRA,José Luiz Cintra
MIRANDA,Milton Edson
Use of botulinum toxin type a in temporomandibular disorder
author_facet HUAMANI,Mary Akemy Uehara
MOREIRA,Luciano Artioli
ARAÚJO,Ney Soares de
NAPIMOGA,Marcelo Henrique
JUNQUEIRA,José Luiz Cintra
MIRANDA,Milton Edson
author_sort HUAMANI,Mary Akemy Uehara
title Use of botulinum toxin type a in temporomandibular disorder
title_short Use of botulinum toxin type a in temporomandibular disorder
title_full Use of botulinum toxin type a in temporomandibular disorder
title_fullStr Use of botulinum toxin type a in temporomandibular disorder
title_full_unstemmed Use of botulinum toxin type a in temporomandibular disorder
title_sort use of botulinum toxin type a in temporomandibular disorder
description ABSTRACT Temporomandibular disorder (TMD) may be defined as a set of clinical scenarios involving the masticatory muscles, the temporomandibular joint (TMJ) and associated structures. Currently, 40 to 75% of the population has some sign of temporomandibular disorder, mainly pain located in the muscles of mastication in the pre-auricular region. The present clinical case was diagnosed as muscle temporomandibular disorder secondary to parafunction, as well as muscle hyperactivity due to surgical displacement of the left temporal muscle on two occasions, one for placement of aneurysm clips and the other for tumor excision from the supraorbital region on the left side. The patient sought medical and dental attention for 10 years due to constant headaches, tiredness and pain in the cheeks. The patient tried numerous bite-guards and pharmacological therapies to no avail. The American Academy of Orofacial Pain Questionnaire was applied combined with the Criteria for Research and Diagnostics (DRC) and a decision was made to use botulinum toxin type A in the masseter and temporalis muscles. An analog pain scale was applied over 90 days. Three days following the application of botulinum toxin type A, the patient reported a significant improvement with complete resolution of pain (level 0) after 90 days. At 12 weeks from starting treatment, facial muscle physiotherapy was introduced to strengthen the muscles of mastication and the patient remained pain-free, which allowed the preparation and adaptation of a snap-on prosthetic appliance. In conclusion, the use of botulinum toxin in patients with temporomandibular disorder should be considered as a viable therapeutic option.
publisher Faculdade São Leopoldo Mandic
publishDate 2017
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1981-86372017000200151
work_keys_str_mv AT huamanimaryakemyuehara useofbotulinumtoxintypeaintemporomandibulardisorder
AT moreiralucianoartioli useofbotulinumtoxintypeaintemporomandibulardisorder
AT araujoneysoaresde useofbotulinumtoxintypeaintemporomandibulardisorder
AT napimogamarcelohenrique useofbotulinumtoxintypeaintemporomandibulardisorder
AT junqueirajoseluizcintra useofbotulinumtoxintypeaintemporomandibulardisorder
AT mirandamiltonedson useofbotulinumtoxintypeaintemporomandibulardisorder
_version_ 1756435350056599552